Journey Medical Corporation's DERM shares rose 10% on Mar 18, after the company announced that its new drug application (NDA) for its key pipeline candidate, DFD-29 capsules (40mg), to treat ...
Hosted on MSN
Hutchmed Stock Hits Over One-Month High After China Accepts Kidney Cancer NDA Filed With Partner Innovent Biologics
Shares of Hutchmed (China) hit their highest levels in over a month after the company announced along with Innovent Biologics that their NDA for a kidney cancer treatment had been accepted by China's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback